Addressing the NSCLC Puzzle Diagnosis, Staging, and Treatment Regimens: Putting All the Pieces Together

A CME/CE Certified Oncology Expert Commentary Webcast

With incidence and death rates in the United States within close range (86.4 vs 73.5/100,000 in males), the need for improved detection and treatment of non-small cell lung cancer (NSCLC) is evident. NSCLC accounts for approximately 87% of lung cancers and is treated using a combination of chemotherapy, surgery, and radiation therapy. The use of chemotherapeutic agents has recently expanded with the advent of biological, targeted drugs that have demonstrated improved efficacy with tolerable toxicities. The ongoing question of how to optimize therapy is being addressed through the development of molecular markers such as excision repair cross-complementing gene 1 (ERCC1) and through continued clinical trials that examine various combinations of targeted and chemotherapeutic drugs. The needed improvement in detection, the ongoing development of molecular and tissue markers, and the discovery of novel agents active against lung cancer all require continued learning by the practicing oncologist. This educational activity will provide the attendee with an overview of the current clinical trial data on NSCLC while highlighting diagnostic tools, current first- and second-line approaches to manage advanced disease, and developments in maintenance therapy. Finally, strategies to individualize therapy will be reviewed.

Available until March 17, 2012, this activity offers:
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour

This activity is sponsored by The University of Texas MD Anderson Cancer Center.